Cue Biopharma (CUE) AI Stock Analysis

• Market Cap: $59.94M
• Dividend Yield: N/A
• Average Volume (3M): 127.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.87
• Revenue Growth: -0.11%
• EPS Growth: 43.47%
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 52
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 76,845,900
• 10 Day Avg. Volume: 140,280
• 30 Day Avg. Volume: 127,345
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.76
• Enterprise Value/Revenue: 5.46
• Enterprise Value/Gross Profit: 5.53
• Enterprise Value/Ebitda: -1.24
• 1Y Price Target: $4.00
• Price Target Upside: 412.82% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 45 Neutral
• Price Target: $1.00 ▲(28.21% Upside)

The overall stock score is primarily impacted by significant financial challenges, including persistent losses and negative cash flows. While the technical analysis provides some neutral signals, the valuation remains weak due to a negative P/E ratio. The recent corporate event offers a slight positive, potentially improving financial flexibility.

Positive Factors

Partnership and Collaborations

With a potential partnership upcoming for CUE-501 and a cash position of $22.5MM, Cue remains an attractive investment opportunity with upside potential if a partnership materializes.

Product Development

Cue regained the global rights for CUE-401 from Ono and expects to submit an IND, indicating progress in their product development pipeline.

Negative Factors

Clinical Development Challenges

The presence of confounding variables and lack of a partner may hinder the clinical development progress of CUE-101.

Program Deprioritization

The company has deprioritized its oncology programs, which may impact its current focus and resources.

Cue Biopharma Business Overview & Revenue Model

Company Description

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Cue Biopharma generates revenue primarily through a combination of research and development collaborations, licensing agreements, and potential milestone payments from partnerships with pharmaceutical companies. The company may also receive funding through grants and investments aimed at advancing its clinical programs. By collaborating with larger pharmaceutical firms, Cue Biopharma can leverage its unique technology platform while sharing the financial risks associated with drug development. Additionally, successful clinical trials can lead to revenue generation through product sales, royalties, and further licensing agreements as therapies progress through various stages of development.

Cue Biopharma Financial Statement Overview

Summary

Cue Biopharma is facing significant financial challenges, characterized by persistent losses and negative cash flows. While there is some revenue growth, the company's profitability and cash generation remain under pressure. The balance sheet shows moderate leverage, but the negative return on equity and ongoing cash burn pose risks to financial stability. Strategic improvements in cost management and operational efficiency are crucial for future financial health.

Income Statement

Cue Biopharma's income statement reveals significant challenges in profitability, with negative net profit margins and EBIT margins over the TTM period. Although there is a slight revenue growth, the company struggles with high operating losses, indicating inefficiencies in cost management. The gross profit margin is relatively high, suggesting potential for improvement if operational costs are controlled.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating manageable leverage. However, the negative return on equity highlights the company's inability to generate profits from shareholders' investments. The equity ratio is stable, but the overall financial health is weakened by consistent losses.

Cash Flow

Cash flow analysis indicates negative operating cash flow and free cash flow, reflecting ongoing cash burn. The free cash flow to net income ratio is slightly above 1, suggesting that cash outflows are closely aligned with net losses. The company faces challenges in generating positive cash flows, which could impact its liquidity position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.29M	9.29M	5.49M	1.25M	14.94M	3.15M
Gross Profit	8.19M	9.29M	-32.61M	-560.83K	16.72M	-30.39M
EBITDA	-36.52M	-37.53M	-46.05M	-50.49M	-45.44M	-43.99M
Net Income	-38.90M	-40.67M	-50.73M	-52.80M	-44.16M	-44.78M
Balance Sheet
Total Assets	40.71M	32.19M	61.53M	91.28M	83.40M	99.53M
Cash, Cash Equivalents and Short-Term Investments	27.49M	22.46M	48.51M	76.29M	64.37M	84.87M
Total Debt	7.63M	8.88M	14.70M	19.32M	10.05M	7.15M
Total Liabilities	22.55M	14.69M	24.45M	25.60M	17.91M	20.62M
Stockholders Equity	18.16M	17.50M	37.09M	65.68M	65.49M	78.91M
Cash Flow
Free Cash Flow	-28.32M	-36.40M	-39.96M	-41.98M	-39.75M	-33.09M
Operating Cash Flow	-28.14M	-36.33M	-39.96M	-41.81M	-38.84M	-32.49M
Investing Cash Flow	-80.00K	32.00K	25.00M	-24.61M	9.11M	4.46M
Financing Cash Flow	25.69M	10.24M	11.86M	53.66M	19.23M	58.61M

Cue Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.78
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CUE, the sentiment is Negative. The current price of 0.78 is below the 20-day moving average (MA) of 0.81, below the 50-day MA of 0.80, and below the 200-day MA of 0.95, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.51 is Neutral, neither overbought nor oversold. The STOCH value of 8.81 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CUE.

Cue Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	61 Neutral	$376.00M	3.99	108.21%	―	18.01%	306.76%
Sector *	51 Neutral	$7.95B	-0.40	-42.50%	2.21%	22.29%	-1.85%
PDSB	50 Neutral	$55.96M	―	-156.16%	―	―	25.26%
CUE	45 Neutral	$59.94M	―	-195.55%	―	-0.11%	43.47%
MAIA	44 Neutral	$50.81M	―	-459.53%	―	―	62.69%
PYPD	41 Neutral	$35.16M	―	-312.77%	―	―	61.18%
STRO	40 Neutral	$89.86M	―	-347.64%	―	-38.31%	-36.91%

Cue Biopharma Corporate Events

Cue Biopharma Amends License Agreement with MIL 40G

On June 30, 2025, Cue Biopharma, Inc. and MIL 40G, LLC amended their License Agreement, resulting in a reduced monthly rental rate from $235,883.98 to $147,545.69, effective immediately, with a 4% increase scheduled for April 15, 2027. Additionally, the agreement’s term was extended to April 14, 2028, and Cue Biopharma received a partial rent credit for June 2025, potentially improving its financial standing and operational flexibility.

Cue Biopharma CFO Resignation and Board Appointment

On June 4, 2025, Cue Biopharma, Inc. appointed Jill Broadfoot to its board of directors, where she will serve as Chair of the Audit Committee. Additionally, the company’s stockholders approved the 2025 Stock Incentive Plan during the annual meeting. On the same day, Kerri-Ann Millar announced her resignation as Chief Financial Officer, effective June 13, 2025, with CEO Daniel R. Passeri stepping in as interim CFO. Furthermore, the company filed a Certificate of Amendment to increase its authorized shares of capital and common stock, reflecting strategic growth initiatives.